In COVID-19 clinical update #124, Dr. Griffin discusses the results of a variant vaccine booster trial, the neutralization of variant sub-lineages by Novavax, the CDC’s recommendation of Novavax’s COVID-19 vaccine in adults, Paxlovid in patients who are immunocompromised and hospitalized, and inhaled fluticasone for outpatient treatment.
Click arrow to play
Download TWiV 921 (24 MB .mp3, 41 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Variant vaccine boosters trial (medRxiv) 10:30
- Novavax triggers neutralization of variant sub-lineages (bioRxiv) 12:58
- CDC recommends Novavax (CDC) 14:04
- Paxlovid in patients who are immunocompromised and hospitalized (The Lancet) 17:21
- Inhaled Fluticasone for outpatient treatment (medRxiv) 21:02
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Contribute to FIMRC fundraiser at PWB 25:09
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 921 25:46
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Now that the FDA has authorized pharmacists to prescribe and dispense Paxlovid, how does one find a pharmacy that will do it? I have asked some of my local pharmacies about this (including CVS), and they all say “we do not follow that protocol”.
I got Evusheld in February 2022. It is supposed to provide protection for six months, and it has been that. My rheumatologist said there is no recommendation to administer it again. Are there studies to show that it is still effective beyond six months? What is the thinking on additional doses for immunosuppressed people? Thank you!